I probably won't speak to the specifics of some of the contracts because I'm a little unsure of my footing in terms of what is covered by business confidentiality and what is not. The specifics on those might be directed to Public Services and Procurement.
What I can say is that Minister Bains and the ISED ministry have certainly been involved in this. There has been a great deal of work to build up and support the Canadian domestic biomanufacturing sector. As has already been noted in the media, a number of these leading international vaccine candidates actually have Canadian technology in them. There are actually Canadian players that are kind of part of it.
The government has made investments in companies such as AbCellera in British Columbia is a good example. It is is manufacturing or has discovered and is involved in the production of a leading monoclonal antibody candidate. This has helped deal with the symptoms and the severity of COVID-19. The government has invested in vaccines; domestically, Medicago in Quebec City is perhaps the best example. This technoloy is very well regarded, and there was a major investment in Medicago.
The government has also invested in the expansion of production capacity, for example, at the National Research Council's Royalmount facility in Montreal to be able to produce a much larger number of doses. That build-out is happening right now.
In concert with the work to secure vaccines from the international sphere, there has been a parallel line of work—quite an aggressive one—to build up Canadian capacity and to invest in promising Canadian candidates and in Canadian manufacturing. Obviously, there's been a lot of international press on the international candidates, but this Canadian side of the story perhaps needs some telling as well. It has been a key feature of our work.